CA
NZ
UK
AU
IND
US
…
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. The company engages in pursuing new product candidates and platforms to build a pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Mosaic Immunoengineering Inc appears to be a small, development-stage biotechnology company focused on immunoengineering technologies for vaccine and therapeutic development. Long-term growth may be driven by successful advancement of its technology platform through preclinical or clinical milestones and by licensing or partnership deals, and investors may find the company attractive for early-stage platform upside and milestone-driven value creation. The principal risks include limited public disclosure, high clinical and regulatory uncertainty, the need for additional financing, and low liquidity typical of OTCQB-listed microcap issuers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-05-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-05-31 | 2022-12-31 |
| Income before tax | -0.69M | -0.92M | -1.01M | -2.38M | -2.38M |
| Net income | -0.69M | -0.92M | -1.01M | -2.38M | -2.38M |
| Selling general administrative | 0.55M | 0.70M | 0.96M | 1.58M | 1.58M |
| Ebit | - | - | - | -2.63M | -2.63M |
| Ebitda | - | - | - | -2.23M | -2.23M |
| Operating income | -0.62M | -0.88M | -1.40M | -2.63M | -2.63M |
| Interest expense | 0.08M | 0.08M | 0.09M | 0.15M | 0.15M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.08M | -0.08M | -0.09M | -0.15M | -0.15M |
| Income tax expense | - | - | - | 0.00M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 0.62M | 0.88M | 1.40M | 2.63M | 2.63M |
| Total other income expense net | 0.01M | 0.04M | 0.48M | 0.40M | 0.40M |
| Net income from continuing ops | -0.69M | -0.92M | -1.01M | -2.38M | -2.38M |
| Net income applicable to common shares | - | - | - | -2.38M | -2.38M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-05-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-05-31 | 2022-12-31 |
| Total assets | 0.02M | 0.14M | 0.18M | 0.26M | 0.26M |
| Other current assets | 0.02M | 0.03M | 0.02M | 0.04M | 0.04M |
| Total liab | 7.50M | 6.93M | 6.05M | 5.15M | 5.15M |
| Total stockholder equity | -7.48M | -6.79M | -5.87M | -4.88M | -4.88M |
| Other current liab | 0.18M | 0.18M | 0.18M | 0.22M | 0.22M |
| Common stock | - | - | - | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -9.53M | -8.84M | -7.92M | -6.91M | -6.91M |
| Cash | 0.00M | 0.12M | 0.16M | 0.22M | 0.22M |
| Total current liabilities | 6.03M | 5.54M | 4.73M | 3.92M | 3.92M |
| Net debt | 1.66M | 1.48M | 1.16M | 1.01M | 1.01M |
| Short long term debt | 0.20M | 0.20M | - | - | - |
| Total current assets | 0.02M | 0.14M | 0.18M | 0.26M | 0.26M |
| Net tangible assets | - | - | - | -4.88M | -4.88M |
| Long term debt | 1.47M | 1.39M | 1.32M | 1.23M | 1.23M |
| Accounts payable | 0.13M | 0.13M | 0.12M | 0.13M | 0.13M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-05-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-05-31 | 2022-12-31 |
| Investments | - | 0.00M | 0.43M | 0.34M | 0.34M |
| Change to liabilities | - | - | - | 0.02M | 0.02M |
| Total cashflows from investing activities | - | - | - | 0.34M | 0.34M |
| Net borrowings | 0.00M | 0.20M | 0.00M | 0.34M | 0.34M |
| Total cash from financing activities | 0.00M | 0.20M | 0.00M | 0.34M | 0.34M |
| Change to operating activities | - | - | - | 1.62M | 1.62M |
| Net income | -0.69M | -0.92M | -1.01M | -2.38M | -2.38M |
| Change in cash | -0.11M | -0.04M | -0.06M | -0.01M | -0.01M |
| Begin period cash flow | 0.12M | 0.16M | 0.22M | 0.23M | 0.23M |
| End period cash flow | 0.00M | 0.12M | 0.16M | 0.22M | 0.22M |
| Total cash from operating activities | -0.11M | -0.24M | -0.50M | -0.69M | -0.69M |
| Change to netincome | - | - | - | 0.05M | 0.05M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.50M | 0.57M | 0.88M | 1.64M | 1.64M |
| Stock based compensation | 0.00M | 0.00M | 0.02M | 0.30M | 0.30M |
| Other non cash items | 0.07M | 0.11M | 0.09M | -0.19M | -0.19M |
| Free cash flow | -0.11M | -0.24M | -0.50M | -0.69M | -0.69M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CPMV Mosaic Immunoengineering Inc |
- -% |
0.14 | - | 10.81 | 96.57 | 9.33 | 72.63 | 105.80 |
| NVO Novo Nordisk A/S |
0.80 2.03% |
39.94 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
19.54 3.62% |
559.54 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
93.31 11.40% |
912.08 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. The company engages in pursuing new product candidates and platforms to build a pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.
9114 Adams Avenue, Huntington Beach, CA, United States, 92646
657-208-0890
2
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven W. King | Chairman, Pres & CEO | 1964 |
| Mr. Paul J. Lytle CPA | Exec. VP, CFO, Sec. & Director | 1968 |
| Dr. Nicole Franziska Steinmetz Ph.D. | Acting Chief Scientific Officer & Director | 1980 |
| Jay Carlson | Sr. Mang. of Investor Relations | NA |
| Mr. Joseph S. Shan M.P.H. | Head of Clinical Operations | 1973 |
| Dr. Marvin R. Garovoy M.D. | Head of Medical Immuno-Oncology | 1944 |
| Cyril Empig Ph.D. | Head of Vaccine Devel. | NA |
| Mr. Steven W. King | Chairman of the Board, President, CFO & CEO | 1964 |
| Mr. Paul J. Lytle CPA | Secretary | 1968 |
| Cyril Empig Ph.D. | Head of Vaccine Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-2.08%
Communication Services
-0.42%
Consumer Cyclical
-0.25%
Consumer Defensive
+0.37%
Energy
-0.13%
Financial Services
-0.90%
Financials
+2.38%
Healthcare
-1.56%
Industrials
-1.07%
Real Estate
-0.26%
Technology
-3.38%
Utilities
-0.36%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...